Ardea Biosciences, Inc./DE
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | FY09 | |
|---|---|---|---|
| Revenue | $7.3M | $27.4M | $22.9M |
| Operating income | −$86.7M | −$41.1M | −$30.0M |
| Net income | −$86.6M | −$41.6M | −$30.9M |
| Total assets | $104.2M | $100.5M | — |
| Total liabilities | — | — | — |
| Equity | $82.2M | $77.1M | $24.7M |
| EPS (diluted) | — | — | — |
| Shares out. | 26.9M | 23.4M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- −1186.3%
- Net margin
- −1185.2%
- Return on equity
- −105.3%
- Return on assets
- −83.1%
- Return on capital (ROCE)
- −104.8%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $3.06
- Revenue growth (YoY)
- −73.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Accruals / assets
- −25.5%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 22, 2012
- Other material eventJun 13, 2012
- Shareholder vote · Other material eventJun 5, 2012
- Regulation FD disclosureMay 30, 2012
- Results of operationsMay 7, 2012
- Entered a material agreement · Other material eventApr 24, 2012
- Director / officer changeApr 2, 2012
- Results of operationsMar 9, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ASCHEDULE 13G (AMENDMENT NO. 6)Feb 14, 2013
- 15-12BJul 2, 2012
- 8-KFORM 8-KJun 22, 2012
- SC 13D/AJun 21, 2012
- 4Jun 21, 2012
- SC 13D/AJun 21, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012
- EFFECTJun 20, 2012